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ABSTRACT 
Objective: Lipid disturbances following treatment with second-generation 
antipsychotics (SGA) represent a major health concern. A previous study 
determined that early changes of plasma lipid levels ≥5% during the first month of 
treatment with SGA predicts further lipid worsening and development of 
dyslipidemia. This study aimed to determine the proportion of adolescents with early 
lipid changes ≥5% and who develop dyslipidemia during SGA treatment. Methods: 
Data were obtained from a 1-year longitudinal study ongoing since 2007 including 
53 adolescent psychiatric (ICD-10) patients (median 16.5 years; IQR: 14.8–17.5 
years) whose metabolic parameters were monitored prospectively during treatment. 
Plasma lipid levels (total (TC), low-density lipoprotein (LDL-C), high-density 
lipoprotein (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and 
fasting triglycerides (TG)) were measured at baseline and after 1, 3 and/or 12 
months of SGA treatment.  Results:  Half (n=26; 49%) of adolescents had early 
increase of TC levels by 5% or more during the first month of treatment and one 
third (n=8; 33%) developed new-onset hypercholesterolemia during the first year of 
treatment. Hypercholesterolemia developed more frequently in female patients (p = 
0.01) and in patients with an early increase of total cholesterol ≥5% (p = 0.02). 
Finally, patients whose HDL-C levels decreased by ≥5% during the first month of 
treatment had a larger HDL-C worsening after three months of treatment as 
compared to others (p = 0.02). Conclusion: This study reminds the importance to 
monitor metabolic parameters prospectively also in adolescents after the 
introduction of SGAs.  
INTRODUCTION 
Patients suffering from severe mental illness such as schizophrenia, bipolar disorder, and 
major depressive disorders have a 10- to 25-year reduced life expectancy compared to 
individuals from the general population1-10, which is mainly attributable to cardiovascular 
diseases resulting from the metabolic syndrome11.  Multiple risk factors implying complex 
mechanisms may explain this excessive susceptibility for developing cardiovascular 
diseases, including psychiatric disease-related factors, an unhealthy lifestyle, poverty, 
and adverse effects of treatment12,13.  Thus, although commonly prescribed to reduce 
psychotic and manic symptoms of schizophrenia and bipolar disorders, the use of 
psychotropic medications such as antipsychotics (most atypical but also some typical), 
mood stabilizers (e.g., lithium and valproate) and some antidepressants (e.g., 
mirtazapine) can increase the risk of metabolic disorders, including obesity and 
dyslipidemia14,15. Multiple factors have been associated with psychotropic drug-induced 
metabolic complications, including low baseline BMI, young age and no previous 
exposure to any psychotropic drug, making adolescents particularly susceptible to the 
development of adverse metabolic effects13,16. In addition, some studies, albeit 
controversial, suggested that women have a greater vulnerability to psychotropic drug-
induced weight gain than men 12,17. 
Adverse metabolic effects such as weight gain are difficult to manage and can have 
potential long-term cardiometabolic consequences, especially in young patients16,18-20. 
Other metabolic parameters (e.g. lipid profile) can also be worsened in young patients 
treated with antipsychotics,19,21-24 which dramatically enhances the risk for long-term 
cardiovascular morbidity and mortality25. Thus, the propensity to develop dyslipidemia 
(defined as high total cholesterol (TC) and/or high LDL-cholesterol (LDL-C), and/or low 
HDL-cholesterol (HDL-C) and/or high non-HDL cholesterol (non-HDL-C) and/or high 
triglyceride (TG) levels) in a young patient who receives an antipsychotic medication was 
estimated to be two- to threefold higher than in a patient who does not receive this type 
of medication26. In addition, this metabolic condition was shown to reach 55% in patients 
with first episode schizophrenia who receive antipsychotic treatment 27. Therefore, regular 
monitoring for metabolic parameters in patients receiving the abovementioned drugs is 
an important issue. Some programs have proposed monitoring of metabolic parameters 
during treatment in patients receiving psychotropic drugs known to induce metabolic 
disturbances, including a close monitoring during the first three months of treatment 28,29. 
Recent studies recognized that components of the metabolic syndrome may develop 
early during psychotropic treatment and may initiate a steady process leading to 
cardiometabolic diseases in the long term19,20,30-32. In particular, lipogenic adverse effects 
may occur very early during treatment and may even precede weight gain13,19,33-35. Our 
research group recently demonstrated the importance of early (i.e., after one month of 
treatment) changes of lipid levels to predict worsening of the lipid profile and development 
of dyslipidemia in the longer term of treatment (≥3 months of treatment)31. In particular, 
patients whose lipid levels increased by 5% or more during the first month of psychotropic 
treatment were more prone to have a considerable worsening of their lipid profiles after 
three months of treatment and to develop dyslipidemia, as compared to other patients31. 
Interestingly, these early lipid-change predictors were applicable in age-stratified 
samples, showing an age-independence and suggesting that they were also valid in 
adolescent patients. However, further characterization of lipid-profile worsening in 
adolescents could not be assessed due to an insufficient number of patients ≤ 18 years 
(n = 16). Although some prospective studies observed that some antipsychotics (e.g., 
olanzapine, quetiapine, or risperidone) induced significant lipid abnormalities in children 
and adolescents 19,36,37, plasma lipid levels were not measured in the early period of 
treatment (i.e., within the first month), which would have been beneficial. 
Because of the high morbidity and mortality associated with dyslipidemia, an early 
detection of adolescent patients at risk for developing lipid disturbances during 
psychotropic treatment is of major clinical concern. The aim of the present study was 
to determine the proportion of patients with early lipid change ≥5% and to measure the 
incidence of new onset dyslipidemia during treatment with psychotropic drugs. Our 
secondary purpose was to identify demographic and clinical risk factors associated 
with worsening of the lipid profile. 
  
METHODS 
Study design 
A longitudinal observational study has been ongoing since 2007 in the Department of 
Psychiatry of the Lausanne University Hospital38. Patients starting a pharmacological 
treatment that is known to have a potential risk to induce metabolic disturbances (i.e. 
an antipsychotic, mood stabilizer or antidepressant listed in Supplementary Table 1) 
were included, as described in the flowchart (Supplementary Figure 1). The present 
study included patients with informed consent from an ongoing pharmacogenetic study 
(PsyMetab) as described elsewhere39. In addition, data of patients in the clinical follow-
up (PsyClin) in our department were also analyzed. Due to the noninterventional post 
hoc analysis study design, no informed consent was requested from the patients who 
had clinical follow-up. Both studies were approved by the Ethics Committee of the 
Canton of Vaud (CER-VD).  
Diagnoses were based on the International Classification of Diseases 10th (ICD-10): 
F10-19: psychoactive substance use; F20-29: schizophrenia; F30-39: mood disorders; 
F40-48: stress related disorders; F50-59: behavioral syndromes; F70-79: mental 
retardation; F80-89: psychological development; F90-98: behavioral and emotional 
disorders. Only patients treated with second-generation antipsychotics (SGA) and with 
available lipid levels at least at baseline and at first month (15 to 45 days of treatment; 
median of 29 days, IQR: 24–32) without any lipid-lowering drug (listed in 
Supplementary Table 2) were included in the sample used for descriptive statistics of 
early lipid changes (i.e., data 1; n = 53). Of note, 63% of patients were not drug naïve. 
Patients whose lipid levels were available at baseline, at first month, and later during 
treatment (median of 92 days, IQR: 80–101, range 56-447) and who did not meet 
criteria for dyslipidemia at baseline were included in the second sample, which was 
used to describe the development of dyslipidemia during psychotropic treatment in 
function of lipid changes at first month (i.e., data 2; n ≤ 25). The majority of blood 
samples were drawn in the morning in fasting conditions. Non-fasting blood samples 
(i.e. within 6 hours following the last meal) were excluded only for triglyceride (TG) 
analysis (not for total (TC), HDL- (HDL-C), LDL- (LDL-C) and non-HDL- (non-HDL-C) 
cholesterol) 40,41. As mentioned previously, 16 patients ≤ 18 years included in the 
present study were already included in a recent study designed to determine the best 
early thresholds for predicting further important lipid worsening31. However, this 
number was insufficient to conduct additional analyses specifically in young patients. 
The present study design enabled to include a greater number of participants (i.e., 37 
new patients, for a total of 53). 
 
Quantification of plasma lipids 
Clinical chemistry assays from plasma samples collected before and after January 2009 
were performed at the Unit of Pharmacogenetics and Clinical Psychopharmacology and 
at the Clinical Laboratory of the Lausanne University Hospital, respectively (both 
laboratories are ISO 15189 certified), using enzymatic colorimetric assays (Roche 
Modular P chemistry analyzer, Roche Diagnostics, Basel, Switzerland, respectively). 
Coefficients of variation for these assays were of ≤1.6%, ≤2% and ≤2.8% for TC, TG and 
HDL-C measurements, respectively. Low HDL-cholesterol level, i.e. HDL 
hypocholesterolemia was defined as < 1 mmol/l, high LDL-cholesterol level, i.e. LDL 
hypercholesterolemia was defined as ≥ 3 mmol/l, high triglyceride level, i.e. 
hypertriglyceridemia was defined as ≥ 2 mmol/l and high total cholesterol level, i.e. 
hypercholesterolemia was defined as ≥ 5 mmol/l, according to ESH/ESC guidelines 42. 
LDL-C was calculated using the Friedewald formula only when TG levels were lower than 
3.5 mmol/l (310 mg/dL) 43,44. Non-HDL-C was calculated from TC minus HDL-C. 
 
Statistical analyses 
In order to compare distribution of demographic and clinical variables across patient’s 
groups, Wilcoxon-Mann-Whitney rank-sum tests and chi-squared tests were 
conducted for comparison of continuous variables and of categorical variables, 
respectively. For comparison of metabolic parameters between baseline and after one 
month of treatment, McNemar tests were performed. 
 
Short- and long-term lipid changes 
The influence of early lipid changes on long-term lipid changes was estimated by fitting 
linear mixed effect models on long-term lipid changes adjusting for age, gender and 
early weight gain groups (>4% versus ≤4%20)  .  
 
Short-term lipid changes and new-onset dyslipidemia 
Kaplan-Meier estimates with log-rank tests were conducted to compare the incidence 
of new-onset dyslipidemia across patients with or without early lipid change ≥5%. For 
survival multivariate analyses, Cox regression tests were conducted, adjusting for age, 
gender, psychotropic drug category (olanzapine and quetiapine being associated with 
the highest risk of dyslipidemia; other drugs conferring a moderate risk 15), and early 
weight gain (>4%20), using the survival package of R. 
Statistical significance was determined by a p-value ≤0.05. Statistical analyses were 
performed using Stata 14 (StataCorp, College Station TX, USA) and R environment for 
statistical computing version 3.3.1. 
  
RESULTS 
Demographics and evolution of lipid parameters 
Table 1 displays the demographic and clinical characteristics of the psychiatric sample. 
Fifty-three young patients monitored during treatment with SGA were included. The 
median age was 16.5 years (IQR: 14.8–17.5 years) and mood disorders (F30-F39) 
were the most frequent diagnosis (43%). Quetiapine was the most frequently 
prescribed psychotropic drug (62%), followed by risperidone (23%), olanzapine (13%) 
and amisulpride (2%). Eight out of the 53 patients (15%) received two SGAs. 
Seventeen percent of patients had hypercholesterolemia at baseline, i.e. TC ≥5 mmol/l 
(no patient received any lipid-lowering drug). Of note, in a sample including a higher 
number of patients (with lipid levels not systematically collected after one month of 
treatment (n=111), hypercholesterolemia prevalence was similar (i.e. 15.3%). In the 
present sample of 53 patients, 26 (49%), 23 (43%), 19 (36%), 15 (28%), and 24 
patients (45%) had early changes of ≥ 5% for TC, LDL-C, TG, HDL-C, and non-HDL-
C, respectively during the first month of SGA treatment. More information in Appendix 
1. 
A gender comparison of demographic and of clinical parameters is shown in 
Supplementary Table 3. After the first month of SGA treatment, the prevalence of 
hypercholesterolemia was significantly higher for females than for males (38% versus 
13%; p = 0.04). Similarly, females had significantly higher levels of total cholesterol 
compared to males, both before and after one month of treatment (4.3 mmol/l versus 
3.6 mmol/l; p = 0.02; 4.4 mmol/l versus 3.8 mmol/l; p = 0.004). Finally, quetiapine was 
more prescribed for females than for males (76% vs 46%; p = 0.02). 
 
Influence of short-term lipid changes on long-term lipid changes 
Linear mixed models adjusting for age, gender, early weight gain group (i.e., >4% 
versus ≤4%) and SGA category indicated that patients with early decrease (≥5%) of 
HDL-C had significantly higher decrease of HDL-C (16.2%; p=0.02) after 3 months of 
treatment as compared to patients without early changes of HDL-C (Supplementary 
Table 4). In addition, trends of difference for TC and non-HDL-C increase after 3 
months of SGA treatment were also observed between patients with and without early 
increase of TC and non-HDL-C. Analyses could not be conducted for TG increase due 
to an insufficient number of observations. Of note, as compared to females, males had 
a significantly larger decrease of HDL-C levels (-13%; p = 0.04) and lower increase of 
TC levels (-15%; p=0.05) after 3 months of treatment (data not shown). 
 
Influence of short-term lipid changes on new-onset dyslipidemia 
Among the 53 young patients monitored during treatment with SGA, twenty-four had 
available data for survival analyses, which were used to characterize the development 
of new-onset dyslipidemia from 3 months of treatment (IQR: 80-101 days, range 56-
447 days) (Supplementary Figure 1). Demographic and clinical characteristics of 
patients whose baseline lipid levels were within the normal range are indicated in 
Supplementary Table 5. The proportion of patients who met criteria for dyslipidemia 
at or after 3 months of SGA treatment ranged from 8% (2/24), 8% (2/25), 9% (2/21), 
13% (3/24) to 33% (8/24) for LDL-C, non-HDL-C, HDL-C, TG and TC, respectively. Of 
note, analyses conducted in a higher number of patients (n=79) whose lipid levels at 
first month were not necessarily available (and whose baseline lipid levels were within 
the normal range) showed similar findings, i.e. dyslipidemia incidences of 23%, 11%, 
5%, 7% and 6% for TC, LDL, TG, HDL and non-HDL, respectively. 
 
Baseline TC and LDL-C levels were significantly higher in patients who developed 
dyslipidemia as compared to those who did not (p ≤ 0.02). In addition, patients 
developing TC hypercholesterolemia were more likely to be female (p = 0.009). Finally, 
although age range was narrow in the present psychiatric sample, patients developing 
TC hypercholesterolemia were significantly older as compared to those who did not (p 
= 0.05). Of note, a trend was also observed for higher age to be associated with an 
increased risk of LDL and non-HDL hypercholesterolemia (p = 0.06).  
Development of new-onset dyslipidemia during treatment with SGA is displayed in 
Figure 1. As the incidence of dyslipidemia for LDL-C, TG, HDL-C, and non-HDL-C was 
insufficient to perform multivariate analyses, Cox regression was only conducted on 
TC. Table 2 shows that females were significantly more prone to develop a TC 
hypercholesterolemia compared to males (p = 0.01). In addition, patients whose TC 
levels increased by ≥ 5% during the first month of treatment had a greater susceptibility 
to develop TC hypercholesterolemia as compared to others (p = 0.02). Although large 
confidence intervals were observed due to a small sample size, survival rate curves 
were significantly divided over time, depending on gender, and a trend of difference 
was observed for early thresholds of TC increase (Supplementary Figure 2). 
  
DISCUSSION 
In the present sample of adolescent patients receiving SGA, a worrisome 
hypercholesterolemia prevalence of 17% for total cholesterol was observed at 
baseline, which is comparable to baseline results from a retrospective study including 
first episode patients aged 23.6 years (SD = 5 years) 27. A Spanish pediatric study 
observed a higher proportion of hypercholesterolemia at baseline (26%)36, possibly 
attributable to less stringent criterion used to define hypercholesterolemia (i.e., ≥170 
mg/dL; corresponding to 4.4 mmol/l). In adult patients included in our department, a 
much higher prevalence of baseline hypercholesterolemia was observed (38%31), 
which can be explained by a longer duration of illness and of lifetime exposure to 
psychotropic treatment. 
In the present study, almost half of the adolescents had early lipid changes of ≥ 5% 
(i.e. 49%, 43%, 36%, 28%, and 45% for TC, LDL-C, TG, HDL-C, and non-HDL-C, 
respectively), which is comparable with the proportions previously observed in adults 
(43%, 43%, 57%, 42%, and 47%, respectively)31. Adolescent patients whose lipid 
levels changed by ≥ 5% during the first month appeared to have higher changes of 
lipid levels and a greater tendency to develop hypercholesterolemia during the course 
of a long-term treatment, as compared to patients whose early lipid levels changed by 
< 5%. In accordance with a previous study conducted in our department, which 
included mainly adult patients31, the risk of developing hypercholesterolemia was 
significantly greater for females than for males. These findings are also consistent with 
results from a retrospective adolescent cohort24 and with other studies, albeit 
controversial, suggesting that women have a greater vulnerability to develop 
psychotropic drug-induced metabolic disturbances than men12,17,45. 
In the present study, young females had higher levels of total cholesterol than young 
males, in agreement with results from a recent study on adolescent psychiatric 
inpatients20. Multivariate analyses showed that young females and patients with early 
increase in TC were more likely to develop new-onset hypercholesterolemia as 
compared to others. On the other hand, previous analyses in a sample including a 
higher number of patients (aged 13-89 years) showed that males were more prone 
than females to develop HDL hypocholesterolemia during treatment with psychotropic 
drugs 31. These contrasting results suggest that further studies considering a higher 
number of adolescents should be performed to determine whether the present gender 
difference is replicated. 
Considering the consequences of dyslipidemia on cardiovascular comorbidities, these 
worrisome findings should raise concern about the critical necessity of developing 
clinical strategies to monitor and control lipid levels in young patients receiving 
psychotropic treatments that induce metabolic side effects. According to studies 
conducted between 2000 and 2011 in five countries, only 22% of patients initiating a 
SGA had a lipid profile screen46. Even though local and national guideline 
implementations helped to significantly increase the screening rate (up to 37%), rates 
of testing remain insufficient46. Because we did not have access to information on the 
total cohort of adolescent patients starting a psychotropic medication in our 
Department, we could not calculate its screening rate. However, we observed that 
among 77 adolescents with available parameters collected in the context of metabolic 
follow-up (e.g. weight), only 60 (i.e. 78%) received a blood sample test at baseline. 
These observations are in accordance with another study showing an insufficient 
percentage of metabolic follow up in adolescent patients being prescribed psychotropic 
medications inducing metabolic side effects 47. Finally, in the present study, 13% of the 
patients received olanzapine, a drug without indication in Switzerland in children and 
adolescents, which is known to induce substantial adverse metabolic effects48,49. Thus, 
putting more effort into the dissemination of knowledge and enforcement of guidelines 
would tentatively help to increase the rates of metabolic follow-up and improve the 
quality of life and longevity of young patients 50. 
The findings of the present study need to be considered with some limitations. First, 
although the median age was low, the majority of patients were not drug naïve, and 
the observed lipid levels increase may have resulted from past treatments. However, 
the naturalistic setting of the present study strengthens the clinical validity of the 
present findings. Second, information on environmental changes, such as physical 
exercise or diet habits throughout the treatment, which could have influenced the 
evolution of lipid levels, were not available and, therefore, not taken into account. Third, 
a considerable drop-out rate was observed during the prospective study, reducing the 
number of available observations after three months of treatment, possibly attributable 
to psychiatry-related factors, such as treatment switching, poor medication adherence, 
and/or refusal of patients participate in follow-up. In addition, medication adherence 
was not guaranteed, which could lead to the inclusion of some false negatives, for 
example, patients who did not develop adverse lipid effects because they did not take 
the drug. However, exclusion of such patients might have led to even worse lipid 
outcomes. Finally, in the present study, no patients received other drugs than SGAs 
(i.e. first generation antipsychotics, mood stabilizers or antidepressants). Then, studies 
including adolescents receiving other drugs than SGAs should also be performed to 
evaluate their impact on the worsening of the lipid profile. 
 In conclusion, this study underlines the importance of metabolic monitoring following 
the introduction of SGA in young patients who are particularly susceptible to adverse 
metabolic effects. Further research should focus on finding effective interventions to 
prevent such adverse effects. In case of metabolic disturbance, if clinically possible, 
the causative SGA should be replaced after a careful evaluation of the risk-benefit ratio 
of a drug switch. Considering the major impact of dyslipidemia and its important 
consequences on morbidity and mortality, it is critical that healthcare professionals are 
aware of the risks associated with the prescription of SGA. 
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CLINICAL POINTS 
 
Although early changes of the lipid profile during treatment with psychotropic drugs 
were demonstrated in adults, this side effect has never been evaluated in adolescent 
patients.  
 
Considering the major impact of dyslipidemia on morbidity and mortality, it is critical 
that healthcare professionals monitor and control lipid levels in young patients 
receiving psychotropic treatments that induce metabolic side effects. 
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Table 1. Demographic parameters of patients with or without early modifications of plasma lipid levels  
Demographic All TC  < 5% 
TC  
≥ 5% 
 p- 
value 
LDL-C  
< 5% 
LDL-C 
 ≥ 5 % 
 p- 
value 
TG  
< 5% 
TG  
≥ 5% 
 p- 
value 
HDL-C  
> -5% 
HDL-C  
≤ -5% 
 p- 
value 
non-HDL-C 
 < 5% 
Number of patients 53  (45 for TG) 27 26 26 23 26 19 35 15 26 
                       
Age, median (IQR), y 16.5 (14.8-17.5) 15.6 (14.5-17.0) 
16.9 (15.7-
17.7) 0.02 
15.6 (14.6-
17.4) 
16.9 (16.2-
17.8) 0.05 
16.8 (15.5-
17.6) 
16.6 (14.6-
17.5) 0.6 
16.6 (15.5-
17.1) 
15.8 (14.1-
17.8) 0.86 
15.8 (14.7-
17.4) 
Men, n(%) 24 (44.3) 12 (44.4) 12 (46.2) 0.9 13 (50.0) 11 (47.8) 0.88 10 (38.5) 12 (63.2) 0.1 16 (45.7) 8 (53.3) 0.62 13 (50) 
Smoking, n(%) 20 (37.0) 11 (40.7) 9 (34.6) 0.28 11 (42.3) 8 (34.8) 0.48 11 (42.3) 7 (36.8) 0.65 12 (34.3) 8 (53.3) 0.25 10 (38.5) 
Diagnosis, n(%)                      
Psychoactive substance use (F10-F19) 2 (3.8) 1 (3.7) 1 (3.9) 0.98 1 (3.9) 1 (4.4) 0.93 2 (7.7) 0 0.22 1 (2.9) 1 (6.7) 0.53 1 (3.9) 
Schizophrenia (F20-F29) 7 (13.2) 4 (14.8) 3 (11.5) 0.73 4 (15.4) 2 (8.7) 0.48 3 (11.5) 3 (15.8) 0.68 4 (11.4) 2 (13.3) 0.85 4 (15.4) 
Mood disorders (F30-F39) 23 (43.4) 12 (44.4) 11 (42.3) 0.88 11 (42.3) 11 (47.8) 0.7 12 (46.2) 9 (47.4) 0.94 16 (45.7) 6 (40.0) 0.71 12 (46.2) 
Stress related disorders (F40-F48) 7 (13.2) 2 (7.4) 5 (19.2) 0.2 3 (11.5) 3 (13.0) 0.87 3 (11.5) 3 (15.8) 0.68 4 (11.4) 3 (20.0) 0.42 2 (7.7) 
Behavioral syndromes (F50-F59) 2 (3.8) 1 (3.7) 1 (3.9) 0.98 1 (3.9) 1 (4.4) 0.93 2 (7.7) 0 0.22 2 (5.7) 0 0.35 1 (3.9) 
Mental retardation (F70-F79) 1 (1.9) 0 1 (3.9) 0.3 0 1 (4.4) 0.28 0 0   1 (2.9) 0 0.51 0 
Psychological development disorders (F80-F89) 2 (3.8) 1 (3.7) 1 (3.9) 0.98 0 2 (8.7) 0.13 0 2 (10.5) 0.09 0 2 (13.3) 0.03 0 
Behavioral and emotional disorders (F90-F98) 6 (11.3) 3 (11.1) 3 (11.5) 0.96 4 (15.4) 1 (4.4) 0.2 1 (3.9) 2 (10.5) 0.38 5 (14.3) 0 0.12 3 (11.5) 
Not available 3 (5.7) 3 (11.1) 0 0.08 2 (7.7) 1 (4.4) 0.63 3 (11.5) 0 0.13 2 (5.7) 1 (6.7) 0.9 3 (11.5) 
                      
Medication, n(%)                      
Amisulpride 1 (1.9) 1 (3.7) 0 0.32 1 (3.9) 0 0.34 1 (3.9) 0 0.39 0 1 (6.7) 0.12 1 (3.9) 
Olanzapine 7 (13.2) 1 (3.7) 6 (23.1) 0.04 2 (7.7) 4 (17.4) 0.3 1 (3.9) 4 (21.0) 0.07 5 (14.3) 1 (6.7) 0.45 1 (3.9) 
Quetiapine 33 (62.3) 18 (66.7) 15 (57.7) 0.5 18 (69.2) 13 (56.5) 0.36 17 (65.4) 12 (63.2) 0.88 23 (65.7) 9 (60.0) 0.7 18 (69.2) 
Risperidone 12 (22.6) 7 (25.9) 5 (19.2) 0.56 5 (19.2) 6 (26.1) 0.57 7 (26.9) 3 (15.8) 0.38 7 (20.0) 4 (26.7) 0.6 6 (23.1) 
                       
Polymedication, n(%) a 8/53 (15.1) 6 (22.2) 2 (7.7) 0.14 5 (19.2) 1 (4.4) 0.11 2 (6.9) 6 (26.1) 0.06 3 (8.6) 4 (26.7) 0.09 5 (19.2) 
                       
Psychiatric illness duration, median (IQR), y 2.5 (1.5-5.3) 3.2 (2.0-5.1) 2.2 (1.2-10.0) 0.7 2.2 (1.8-3.5) 2.2 (1.2-8.9) 0.9 2.0 (1.1-4.7) 2.2 (1.5-3.7) 0.71 2.0 (1.2-3.3) 6.3 (2.9-10.3) 0.052 2.2 (2.0-3.3) 
                      
Early weight gain (>4%), n(%)                      
1st month 21 (40.4) 7 (25.9) 14 (56.0) 0.03 6 (23.1) 12 (54.6) 0.03 9 (34.6) 8 (44.4) 0.51 16 (47.1) 3 (20.0) 0.07 8 (30.8) 
                         
   p-value b                  
Total cholesterol, median (IQR), mmol/l                      
Baseline 4.1 (3.4-4.4)   4.3 (3.7-4.5) 3.6 (3.2-4.4) 0.04 4.1 (3.5-5) 3.6 (3.2-4.4) 0.22 4.2 (3.5-4.4) 3.4 (3.2-4.4) 0.38 3.7 (3.2-4.3) 4.3 (3.6-5.2) 0.09 4.2 (3.6-4.5) 
1st month 4.1 (3.8-5) 0.29 4 (3.4-4.4) 4.4 (3.8-5.2) 0.15 4 (3.4-4.4) 4.3 (3.8-5.2) 0.05 4.2 (3.8-5) 3.9 (3.6-4.4) 0.19 4.1 (3.8-5) 4 (3.4-4.6) 0.69 4 (3.4-4.4) 
                      
LDL cholesterol, median (IQR), mmol/l                    
Baseline 2.2 (1.8-2.6)   2.4 (2.0-2.7) 1.8 (1.6-2.4) 0.01 2.3 (1.9-2.7) 1.9 (1.6-2.6) 0.08 2.3 (1.8-2.6) 1.9 (1.6-2.9) 0.63 2.2 (1.7-2.5) 2.4 (1.9-3.0) 0.12 2.3 (1.9-2.6) 
1st month 2.3 (1.8-2.8) 0.54 2.2 (1.8-2.6) 2.4 (1.8-3.3) 0.4 2.1 (1.8-2.4) 2.6 (2.0-3.3) 0.06 2.3 (2.0-3.0) 2.1 (1.7-2.5) 0.32 2.3 (1.9-2.8) 2.1 (1.7-2.9) 0.63 2.2 (1.8-2.5) 
                    
Triglyceride, median (IQR), mmol/l                      
Baseline 1 (0.7-1.2)   1.1 (0.6-1.3) 1 (0.7-1.2) 0.67 1.1 (0.7-1.2) 1 (0.7-1.2) 0.74 1.1 (0.8-1.3) 0.9 (0.6-1.2) 0.17 1 (0.7-1.2) 1.1 (0.8-1.2) 0.85 1.2 (0.7-1.3) 
1st month 0.9 (0.7-1.4) 0.48 1 (0.6-1.4) 1 (0.7-1.4) 0.8 1.1 (0.7-1.4) 0.9 (0.7-1.2) 0.68 0.9 (0.6-1) 1.4 (0.8-1.6) 0.007 0.9 (0.4-1.4) 1.1 (0.8-1.6) 0.12 1 (0.7-1.4) 
                      
HDL cholesterol, median (IQR), mmol/l                      
Baseline 1.2 (1-1.5)   1.2 (1.1-1.7) 1.2 (1-1.4) 0.52 1.2 (1-1.6) 1.2 (1-1.5) 0.86 1.2 (1-1.5) 1.2 (1.1-1.4) 0.98 1.2 (1-1.5) 1.2 (1.1-1.8) 0.35 1.2 (1-1.6) 
1st month 1.3 (1-1.6) 0.66 1.2 (1-1.5) 1.4 (1.1-1.6) 0.32 1.2 (1-1.4) 1.4 (1.1-1.6) 0.11 1.4 (1.1-1.7) 1.2 (1-1.4) 0.054 1.4 (1.1-1.6) 1.1 (0.9-1.2) 0.004 1.1 (1-1.5) 
                      
Hypercholesterolemia (≥ 5 mmol/l), n/total (%)                      
Baseline 9/53 (17.0)   7/27 (25.9) 2/26 (7.7) 0.07 7/26 (26.9) 2/23 (8.7) 0.1 4/26 (15.4) 4/19 (21.0) 0.62 4/35 (11.4) 5/15 (33.3) 0.07 6/26 (23.1) 
1st month 14/53 (26.4) 0.27 3/27 (11.1) 11/26 (42.3) 0.01 3/26 (11.5) 9/23 (39.1) 0.03 8/26 (30.8) 2/19 (10.5) 0.11 10/35 (28.6) 2/15 (13.3) 0.27 2/26 (7.7) 
                    
LDL hypercholesterolemia (≥ 3 mmol/l), n/total (%)                      
Baseline 7/49 (14.3)   5/26 (19.2) 2/23 (8.7) 0.29 5/26 (19.2) 2/23 (8.7) 0.29 2/26 (7.7) 4/19 (21.0) 0.19 3/35 (8.6) 4/14 (28.6) 0.07 4/26 (15.4) 
1st month 10/49 (20.4) 0.45 3/26 (11.5) 7/23 (30.4) 0.1 3/26 (11.5) 7/23 (30.4) 0.1 6/26 (23.1) 3/19 (15.8) 0.55 7/35 (20.0) 3/14 (21.4) 0.88 2/26 (7.7) 
                       
Hypertriglyceridemia (≥ 2 mmol/l), n/total (%)                      
Baseline 1/48 (2.1)   0 1/22 (4.55) 0.27 0 1/23 (4.4) 0.3 1/26 (3.9) 0 0.39 1/33 (3.0) 0 0.51 0 
1st month 4/48 (8.3) 0.5 1/25 (4.0) 3/23 (13.0) 0.26 1/25 (4.0) 2/22 (9.1) 0.48 1/26 (3.9) 2/19 (10.5) 0.38 1/34 (2.9) 3/14 (21.4) 0.04 1/25 (4.0) 
                       
HDL hypocholesterolemia (≤ 1 mmol/l), n/total (%)                      
Baseline 13/50 (26.0)   6/26 (23.1) 7/24 (29.2) 0.62 7/26 (26.9) 6/23 (26.1) 0.95 8/26 (30.8) 4/19 (21.1) 0.47 10/35 (28.6) 3/15 (20.0) 0.53 8/26 (30.8) 
1st month 13/50 (26.0) 1 7/27 (25.9) 6/24 (25.0) 0.94 8/26 (30.8) 4/23 (17.4) 0.28 4/26 (15.4) 6/19 (31.6) 0.2 6/35 (17.1) 7/15 (46.7) 0.03 9/26 (34.6) 
 
Only patients without any lipid-lowering medication were included. P-values were calculated using ranksum tests for continuous variables and Chi2 tests for categorical variables. Values in bold are 
significant. 
a: Eight patients received an additional antipsychotic which may induce metabolic disturbances. More precisely, aripiprazole was co-prescribed once with amisulpride and once with risperidone, while 
amisulpride, aripiprazole, olanzapine and risperidone were co-prescribed with quetiapine in one, one, one and three patients, respectively). 
b: p-values were calculated using McNemar tests to compare metabolic parameters between baseline and 1st month of treatment. 
Abbreviations: HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; non-HDL-C: non-high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglycerides. 
 
  
Table 2. Risk factors for new-onset TC hypercholesterolemia during the first year of psychotropic treatment 
 
NODTC (n=24) 
estimate (SE) p-value
Age   NS 
Sex -4.40 (1.78) 0.01 
Early lipid increase a 4.38 (1.82) 0.02 
Psychotropic medication b   NS 
Early weight gain c   NS 
 
 
Results were obtained by fitting a Cox regression controlling for age, gender, current psychotropic drug and early weight gain >4% group. Cox regressions could not be 
performed on LDL hypercholesterolemia, hypertriglyceridemia and HDL hypocholesterolemia due to an insufficient number of new cases. 
a Early lipid change groups constructed according to 5% thresholds (≥5% versus <5% of TC increase for NODTC model). 
b Risperidone (n=4) versus Quetiapine (n=14) versus Olanzapine (n=6). 
c Early weight gain groups were constructed according to the 4% threshold after one month of treatment 20 (>4% versus ≤4%).   
Abbreviations: NODTC: new-onset hypercholesterolemia for total cholesterol; NS: non significant; SE: standard error.
a.  
b.  
 
c.   
d.  
 
e.  
 
Figure 1. Survival curves for new onset dyslipidemia (NOD) by unadjusted Kaplan-Meier 
curves 
a. Patient survival curve for NODTC (new-onset TC hypercholesterolemia) b. Patient survival 
curve for NODLDL (new onset LDL-C hypercholesterolemia) c. Patient survival curve for 
NODHDL (new onset HDL-C hypocholesterolemia) d. Patient survival curve for NODTG (new 
onset hypertriglyceridemia) e. Patient survival curve for NODnon-HDL (new onset non-HDL-C 
hypercholesterolemia). Dotted lines indicate the 95%CI of the survival curve. 
 
Appendix 1 
 
METHODS 
 
Study design 
Clinical data were either collected during hospitalization or in outpatient centers during a medical 
examination based on the department guideline for the metabolic follow-up of psychotropic drugs 
performed on a routine basis. Follow-up was restarted from baseline if a treatment was stopped 
for more than 2 weeks, if a psychotropic drug was replaced by another, or if a second psychotropic 
drug was added. If two or more follow-ups were available for one patient, only the longest one 
was included in the analysis. 
 
RESULTS 
Some demographic differences were observed between patients whose lipid levels change 
was <5% or ≥5% (Table 1). In particular, patients whose total cholesterol increase was ≥5% 
were slightly older (p = 0.02), were more likely to receive olanzapine (23% versus 4%; p = 
0.04), had significantly lower levels of total cholesterol at baseline (3.6 mmol/l versus 4.3 
mmol/l; p = 0.04), and were more likely to have early weight gain >4% (56% versus 26%; p = 
0.03) as compared to others. Of note, within the different diagnoses, the prevalence of patients 
with or without early lipid worsening was similar. In addition, comparing metabolic parameters 
across the nine different diagnoses did not reveal any significant difference. An increased 
number of patients in the under-represented diagnosis categories (e.g. those with a number of 
patients <10) should provide an increased power and would help to perform a more accurate 
comparison. Finally, patients receiving two SGAs concomitantly were distributed similarly 
across groups of early lipid levels change (Table 1). 
  
Supplementary Table 1. Drugs included in the metabolic follow-up recommendation 
ANTIPSYCHOTICS ANTIDEPRESSANTS MOOD STABILIZERS 
Atypical  
(second-generation) 
Typical  
(first-generation) 
Tricyclic Other   
          
Amisulpride Chlorprothixene Amitriptyline Mirtazapine Carbamazepine 
Aripiprazole Flupentixol Clomipramine   Lithium 
Asenapine Haloperidol Doxepine   Valproate 
Clozapine Levomepromazine Imipramine     
Lurasidone Pipamperone  Nortriptyline     
Olanzapine Promazine  Opipramol     
Paliperidone Sulpiride  Trimipramine     
Quetiapine Tiapride      
Risperidone Zuclopenthixol      
Sertindole 
 
    
         
 
According to international recommendations, a metabolic follow-up is ongoing since 2007 in the Department of Psychiatry at the 
Lausanne University Hospital 1, in which inpatients and outpatients are prospectively monitored when starting a pharmacological 
treatment known to have a potential risk to induce metabolic disturbances (i.e. drugs listed above). The list is based on psychotropic 
drugs available in Switzerland). 
  
 
Supplementary Table 2. Lipid-lowering drugs considered to characterize dyslipidemia 
 
Lipid-lowering 
drugs 
Atorvastatin 
Ezetimibe 
Fenofibrate 
Fluvastatin 
Pravastatin 
Rosuvastatin 
Simvastatin 
 
The list was extracted from 2. This list only provides lipid-lowering drugs prescribed in the present longitudinal observational study.  
  
Supplementary Table 3. Gender comparison of demographic and clinical parameters in patients 
without lipid-lowering comedication 
Demographic Men Women  p- 
value Number of patients 24 29 
       
Age, median (IQR), y 16.1 (14.8-17.5) 16.9 (14.8-17.4) 0.49 
Smoking, n(%) 9 (37.5) 11 (37.9) 0.46 
Diagnosis, n(%)      
Psychoactive substance use (F10-F19) 1 (4.2) 1 (3.5) 0.89 
Schizophrenia (F20-F29) 3 (12.5) 4 (13.8) 0.89 
Mood disorders (F30-F39) 9 (37.5) 14 (48.3) 0.43 
Stress related disorders (F40-F48) 3 (12.5) 4 (13.8) 0.89 
Behavioral syndromes (F50-F59) 0 2 (6.9) 0.19 
Mental retardation (F70-F79) 0 1 (3.5) 0.36 
Psychological development (F80-F89) 2 (8.3) 0 0.11 
Behavioral and emotional disorders (F90-F98) 4 (16.7) 2 (6.9) 0.26 
Not available  2 (8.3) 1 (3.5) 0.44 
      
Medication, n(%)      
Amisulpride 1 (4.2) 0 0.27 
Olanzapine 4 (16.7) 3 (10.3) 0.5 
Quetiapine 11 (45.8) 22 (75.9) 0.02 
Risperidone 8 (33.3) 4 (13.8) 0.09 
       
Polymedication, n(%) a 4 (16.7) 4 (13.8) 0.77 
       
Psychiatric illness duration, median (IQR), y 3.3 (2.0-8.3) 2.2 (1.2-4.7) 0.29 
       
Early weight gain (>4%), n(%)      
1st month 9 (39.1) 12 (41.4) 0.87 
      
      
Total cholesterol, median (IQR), mmol/l      
Baseline 3.6 (3.2-4.3) 4.3 (3.7-4.6) 0.02 
1st month 3.8 (3.3-4.2) 4.4 (4-5.2) 0.004 
      
LDL cholesterol, median (IQR), mmol/l      
Baseline 2.0 (1.6-2.5) 2.4 (1.9-2.7) 0.09 
1st month 2 (1.7-2.6) 2.4 (2.0-2.9) 0.1 
      
Triglyceride, median (IQR), mmol/l      
Baseline 1 (0.6-1.2) 1 (0.7-1.2) 0.56 
1st month 1 (0.8-1.4) 1 (0.7-1.4) 0.84 
      
HDL cholesterol, median (IQR), mmol/l      
Baseline 1.2 (1-1.4) 1.2 (1.1-1.5) 0.42 
1st month 1.1 (1-1.5) 1.4 (1.1-1.7) 0.08 
      
Hypercholesterolemia (≥ 5 mmol/l), n/total (%)      
Baseline 3/24 (12.5) 6/29 (20.7) 0.43 
1st month 3/24 (12.5) 11/29 (37.9) 0.04 
      
LDL hypercholesterolemia (≥ 3 mmol/l), n/total 
(%)   
   
Baseline 3/24 (12.5) 4/25 (16.0) 0.73 
1st month 4/24 (16.6) 6/25 (24.0) 0.52 
       
Hypertriglyceridemia (≥ 2 mmol/l), n/total (%)      
Baseline 0 1/26 (3.9) 0.35 
1st month 1/24 (4.2) 3/24 (12.5) 0.3 
       
HDL hypocholesterolemia (≤ 1 mmol/l), n/total (%)      
Baseline 9/24 (37.5) 4/26 (15.4) 0.08 
1st month 9/24 (37.5) 4/26 (15.4) 0.08 
 
Only patients without any lipid-lowering medication were included. P-values were calculated using rank-sum tests for continuous 
variables and Chi2 tests for categorical variables. Values in bold are significant. 
a: Eight patients received an additional antipsychotic which may induce metabolic disturbances. More precisely, aripiprazole was co-
prescribed once with amisulpride and once with risperidone, while amisulpride, aripiprazole, olanzapine and risperidone were co-
prescribed with quetiapine in one, one, one and three patients, respectively). 
Abbreviations: HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; non-HDL-C: non-high-density 
lipoprotein cholesterol; TC: total cholesterol; TG: triglycerides.
Supplementary Table 4. Linear regressions fitted on lipid trait changes (%) over time 
 
  
 
  
n 
Difference of TC 
change (%) between 
<5% and ≥5% groups 
(95%CI) 
p-value n 
Difference of LDL-C 
change (%) between 
<5% and ≥5% groups 
(95%CI) 
p-value n 
Difference of HDL-C 
change (%) between <5% 
and ≥5% groups (95%CI) 
p-value n 
Difference of non-HDL-
C change (%) between 
<5% and ≥5% groups 
(95%CI) 
p-value 
29 11.5% (-2.2% - 25.2%) 0.10 26 17.8% (-9.2% - 44.9%) 0.19 27 -16.2% (-30.0% - (-) 2.4%) 0.02 27 17.6% (-2.1% - 37.3%) 0.08 
 
 
 
Results were obtained by fitting linear regressions controlling for age, gender, early weight gain group (i.e. >4% versus ≤4%) and psychotropic treatment categories (i.e. olanzapine, 
clozapine, mirtazapine and quetiapine versus other drugs). P-values in bold are significant. Analyses on triglyceride could not be performed due to a too low number of observations. 
Abbreviations: HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; non-HDL-C: non-high-density lipoprotein cholesterol; TC: total cholesterol; TG: 
triglycerides. 
   
Supplementary Table 5. Demographic parameters and comparisons between patients with and without new-onset dyslipidemia during the first 
year of psychotropic treatment 
 
    
Patients without 
NODTC (n=16) 
Patients with 
NODTC (n=8) p-value 
Patients without 
NODLDL (n=22) 
Patients with 
NODLDL (n=2) p-value 
Patients without 
NODTG (n=21) 
Patients with 
NODTG (n=3) p-value 
Patients without 
NODHDL (n=19) 
Patients with 
NODHDL (n=2) p-value 
Patients without 
NODnonHDL 
(n=23) 
    
                  
Age, median (IQR), y 15.6 (14.3-16.6) 17 (16.4-17.6) 0.05 16 (14.6-17) 18 (18-18) 0.06 16.4 (15.5-17.4) 
17.1 (15.6-
17.9) 0.36 16.3 (15.5-17.4) 15.8 (14.1-17.5) 0.81 15.8 (14.6-17.0) 
Men, n(%) 11 (68.8) 1 (12.5) 0.009 11 (50.0) 1 (50.0) 1 12 (57.1) 1 (33.3) 0.44 9 (47.4) 1 (50.0) 0.94 12 (52.2) 
Smoking, n(%) 7 (43.8) 2 (25.0) 0.59 9 (40.9) 1 (50.0) 0.85 9 (42.9) 1 (33.3) 0.67 5 (26.3) 2 (100) 0.11 9 (39.1) 
Diagnosis, n(%)   
                  
  Psychotic disorders 2 (12.5) 2 (25.0) 0.44 3 (13.6) 0 0.58 4 (19.1) 0 0.41 3 (15.8) 1 (50.0) 0.24 3 (13.0) 
  Bipolar disorders 2 (12.5) 0 0.3 3 (13.6) 0 0.58 3 (14.3) 1 (33.3) 0.24 3 (15.8) 0 0.74 4 (17.4) 
  Depressive disorders 7 (43.8) 1 (12.5) 0.13 9 (40.9) 0 0.25 8 (38.1) 2 (66.7) 0.35 8 (42.1) 0 0.24 9 (39.1) 
  Other 4 (25.0) 3 (37.5) 0.53  5 (22.7) 1 (50.0) 0.39 5 (23.8) 0 0.34 4 (21.1) 0 0.47 5 (21.7) 
  Not available 1 (6.3) 2 (25.0) 0.19 2 (9.1) 1 (50.0) 0.09 1 (4.8) 0 0.7 1 (5.3) 1 (50.0) 0.04 2 (8.7) 
    
                  
Medication, n(%)   
                  
  Olanzapine 4 (25.0) 2 (25.0) 1 5 (22.7) 0 0.45 3 (14.3) 1 (33.3) 0.41 4 (21.0) 0 0.47 5 (21.7) 
  Quetiapine 10 (52.5) 4 (50.0) 0.56 14 (63.6) 1 (50.0) 0.7 13 (61.9) 2 (66.7) 0.9 10 (52.6) 2 (100) 0.2 14 (60.9) 
  Risperidone 2 (12.5) 2 (25.0) 0.44 3 (13.6) 1 (50.0) 0.19 5 (23.8) 0 0.34 5 (26.3) 0 0.41 4 (17.4) 
    
                  
Early weight gain (>4%), n(%) 8 (50.0) 3 (37.5) 0.56 9 (40.9) 1 (50.0) 0.8 7 (33.3) 1 (33.3) 1 5 (26.3) 1 (50.0) 0.48 9 (39.1) 
Psychiatric illness duration, median (IQR) years 2.5 (1-7) 6 (1-10) 0.56 3 (1-5) NA   3 (1.5-5) 6 (1-11) 0.71 2.5 (1-4) 4 (4-4) 0.42 3 (1-5) 
Baseline lipid levels a, median (IQR), mmol/l 3.5 (3.2-4) 4.4 (4.3-4.4) 0.002 2.2 (1.6-2.3) 2.8 (2.7-2.9) 0.02 1 (0.6-1.3) 1 (0.9-1.7) 0.33 1.4 (1.2-1.8) 1.2 (1.2-1.2) 0.27 2.5 (2.1-2.9) 
 
 
Only patients with no dyslipidemia at baseline are included. P-values were calculated using rank-sum tests (for continuous variables) and chi2 tests (for categorical variables) between 
groups. Values in bold are significant. 
a Levels of TC for NODTC groups, LDL-C for NODLDL groups, TG for NODTG groups, HDL-C for NODHDL groups and non-HDL-C for NODnonHDL groups. 
Abbreviations: NA: not available; NODHDL: new-onset HDL hypocholesterolemia, defined by plasma levels of HDL cholesterol ≤1 mmol/l (39 mg/dL)*; NODLDL: new-onset LDL 
hypercholesterolemia, defined by plasma levels of LDL cholesterol ≥3 mmol/l (116 mg/dL)*; NODnonHDL: new-onset nonHDL hypercholesterolemia, defined by plasma levels of non-
HDL cholesterol ≥4 mmol/l (154 mg/dL)*; NODTC: new-onset hypercholesterolemia, defined by plasma levels of total cholesterol ≥5 mmol/l (193 mg/dL)*; NODTG: new-onset 
hypertriglyceridemia, defined by plasma levels of triglycerides ≥2 mmol/l (177 mg/dL)*. 
*None of the patients were prescribed lipid lowering agents. 
 
  
  
 
 
 
Supplementary Figure 1. Flowchart of patient selection 
Data 1 were used for the determination of patients who developed an early increase in blood lipid levels. 
Data 2 were used for the determination of risk factors associated with the development of new onset dyslipidemia. 
  
 
 
Supplementary Figure 2. Survival curves for total cholesterol (TC) hypercholesterolemia by 
Kaplan-Meier curves according to clinical parameters 
a. Patient survival curves for NODTC (new onset TC hypercholesterolemia) according to TCi (i.e. early 
5% TC increase) threshold (n=24). Kaplan-Meier p-value=0.06; Cox p-value=0.02.  
 S2 Figure. Survival curves for total cholesterol (TC) hypercholesterolemia by Kaplan-Meier curves 
according to clinical parameters 
b. Patient survival curves for NODTC (new onset TC hypercholesterolemia) according to gender (n=24). Kaplan-
Meier p-value=0.049; Cox p-value=0.01. 
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